nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyldopa—SLC15A1—Proton/oligonucleotide cotransporters—SLC15A2—multiple sclerosis	0.0538	0.314	CbGpPWpGaD
Methyldopa—DDC—pineal body—multiple sclerosis	0.0488	0.227	CbGeAlD
Methyldopa—DDC—nerve—multiple sclerosis	0.0355	0.165	CbGeAlD
Methyldopa—COMT—Neurotransmitter Clearance In The Synaptic Cleft—BCHE—multiple sclerosis	0.0154	0.0897	CbGpPWpGaD
Methyldopa—ADRA2A—peripheral nervous system—multiple sclerosis	0.0153	0.0712	CbGeAlD
Methyldopa—DDC—brainstem—multiple sclerosis	0.0152	0.0707	CbGeAlD
Methyldopa—COMT—brainstem—multiple sclerosis	0.0101	0.0468	CbGeAlD
Methyldopa—Isoprenaline—MAPK1—multiple sclerosis	0.00998	0.808	CrCbGaD
Methyldopa—DDC—midbrain—multiple sclerosis	0.0097	0.0451	CbGeAlD
Methyldopa—DDC—nervous system—multiple sclerosis	0.00797	0.0371	CbGeAlD
Methyldopa—DDC—central nervous system—multiple sclerosis	0.00768	0.0357	CbGeAlD
Methyldopa—DDC—SIDS Susceptibility Pathways—PLP1—multiple sclerosis	0.00757	0.0442	CbGpPWpGaD
Methyldopa—SLC15A1—Amino acid and oligopeptide SLC transporters—SLC15A2—multiple sclerosis	0.00725	0.0423	CbGpPWpGaD
Methyldopa—COMT—medulla oblongata—multiple sclerosis	0.00702	0.0326	CbGeAlD
Methyldopa—COMT—midbrain—multiple sclerosis	0.00641	0.0298	CbGeAlD
Methyldopa—COMT—spinal cord—multiple sclerosis	0.00626	0.0291	CbGeAlD
Methyldopa—DDC—brain—multiple sclerosis	0.00609	0.0283	CbGeAlD
Methyldopa—COMT—nervous system—multiple sclerosis	0.00527	0.0245	CbGeAlD
Methyldopa—COMT—central nervous system—multiple sclerosis	0.00508	0.0236	CbGeAlD
Methyldopa—COMT—cerebellum—multiple sclerosis	0.00496	0.0231	CbGeAlD
Methyldopa—DDC—Amino acid and derivative metabolism—SRM—multiple sclerosis	0.00452	0.0264	CbGpPWpGaD
Methyldopa—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC15A2—multiple sclerosis	0.00427	0.0249	CbGpPWpGaD
Methyldopa—COMT—brain—multiple sclerosis	0.00403	0.0187	CbGeAlD
Methyldopa—ADRA2A—medulla oblongata—multiple sclerosis	0.00357	0.0166	CbGeAlD
Methyldopa—ADRA2A—midbrain—multiple sclerosis	0.00327	0.0152	CbGeAlD
Methyldopa—COMT—Neuronal System—KCNA3—multiple sclerosis	0.0032	0.0187	CbGpPWpGaD
Methyldopa—ADRA2A—spinal cord—multiple sclerosis	0.00319	0.0148	CbGeAlD
Methyldopa—DDC—SIDS Susceptibility Pathways—C4A—multiple sclerosis	0.00315	0.0183	CbGpPWpGaD
Methyldopa—COMT—Biological oxidations—CYP27B1—multiple sclerosis	0.00304	0.0177	CbGpPWpGaD
Methyldopa—COMT—Biological oxidations—CYP24A1—multiple sclerosis	0.00304	0.0177	CbGpPWpGaD
Methyldopa—COMT—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.003	0.0175	CbGpPWpGaD
Methyldopa—COMT—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.003	0.0175	CbGpPWpGaD
Methyldopa—Cardiac failure congestive—Prednisolone—multiple sclerosis	0.00285	0.00474	CcSEcCtD
Methyldopa—Flatulence—Cladribine—multiple sclerosis	0.00285	0.00474	CcSEcCtD
Methyldopa—Diarrhoea—Fingolimod—multiple sclerosis	0.00284	0.00473	CcSEcCtD
Methyldopa—Hepatobiliary disease—Azathioprine—multiple sclerosis	0.00284	0.00473	CcSEcCtD
Methyldopa—Agranulocytosis—Azathioprine—multiple sclerosis	0.0028	0.00467	CcSEcCtD
Methyldopa—Dizziness—Fingolimod—multiple sclerosis	0.00275	0.00458	CcSEcCtD
Methyldopa—ADRA2A—nervous system—multiple sclerosis	0.00269	0.0125	CbGeAlD
Methyldopa—Vasculitis—Prednisone—multiple sclerosis	0.00265	0.00441	CcSEcCtD
Methyldopa—Cardiac failure congestive—Triamcinolone—multiple sclerosis	0.00262	0.00436	CcSEcCtD
Methyldopa—Cardiac failure congestive—Methylprednisolone—multiple sclerosis	0.00262	0.00435	CcSEcCtD
Methyldopa—Headache—Fingolimod—multiple sclerosis	0.0026	0.00433	CcSEcCtD
Methyldopa—Pancytopenia—Mitoxantrone—multiple sclerosis	0.00259	0.00431	CcSEcCtD
Methyldopa—ADRA2A—central nervous system—multiple sclerosis	0.00259	0.012	CbGeAlD
Methyldopa—ADRA2A—cerebellum—multiple sclerosis	0.00253	0.0117	CbGeAlD
Methyldopa—Erectile dysfunction—Mitoxantrone—multiple sclerosis	0.00251	0.00418	CcSEcCtD
Methyldopa—Weight increased—Mitoxantrone—multiple sclerosis	0.00248	0.00413	CcSEcCtD
Methyldopa—Myalgia—Cladribine—multiple sclerosis	0.00246	0.00409	CcSEcCtD
Methyldopa—Arthralgia—Cladribine—multiple sclerosis	0.00246	0.00409	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Cladribine—multiple sclerosis	0.00244	0.00406	CcSEcCtD
Methyldopa—Mediastinal disorder—Azathioprine—multiple sclerosis	0.00243	0.00405	CcSEcCtD
Methyldopa—DDC—SIDS Susceptibility Pathways—AQP4—multiple sclerosis	0.00238	0.0139	CbGpPWpGaD
Methyldopa—Cardiac failure congestive—Dexamethasone—multiple sclerosis	0.00238	0.00396	CcSEcCtD
Methyldopa—Cardiac failure congestive—Betamethasone—multiple sclerosis	0.00238	0.00396	CcSEcCtD
Methyldopa—Epinephrine—TNF—multiple sclerosis	0.00237	0.192	CrCbGaD
Methyldopa—Jaundice—Mitoxantrone—multiple sclerosis	0.00237	0.00394	CcSEcCtD
Methyldopa—Oedema—Cladribine—multiple sclerosis	0.00236	0.00392	CcSEcCtD
Methyldopa—Infection—Cladribine—multiple sclerosis	0.00234	0.0039	CcSEcCtD
Methyldopa—Psychotic disorder—Methylprednisolone—multiple sclerosis	0.00232	0.00386	CcSEcCtD
Methyldopa—Nervous system disorder—Cladribine—multiple sclerosis	0.00231	0.00385	CcSEcCtD
Methyldopa—Thrombocytopenia—Cladribine—multiple sclerosis	0.00231	0.00384	CcSEcCtD
Methyldopa—Skin disorder—Cladribine—multiple sclerosis	0.00229	0.00381	CcSEcCtD
Methyldopa—Agranulocytosis—Mitoxantrone—multiple sclerosis	0.00227	0.00377	CcSEcCtD
Methyldopa—Abdominal distension—Prednisolone—multiple sclerosis	0.00225	0.00374	CcSEcCtD
Methyldopa—Bradycardia—Mitoxantrone—multiple sclerosis	0.00222	0.00369	CcSEcCtD
Methyldopa—Vasculitis—Methotrexate—multiple sclerosis	0.00222	0.00369	CcSEcCtD
Methyldopa—Pancreatitis—Prednisolone—multiple sclerosis	0.00219	0.00365	CcSEcCtD
Methyldopa—Hepatitis—Mitoxantrone—multiple sclerosis	0.00218	0.00363	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Cladribine—multiple sclerosis	0.00215	0.00357	CcSEcCtD
Methyldopa—Breast disorder—Methylprednisolone—multiple sclerosis	0.00214	0.00357	CcSEcCtD
Methyldopa—Paraesthesia—Cladribine—multiple sclerosis	0.00212	0.00352	CcSEcCtD
Methyldopa—Psychotic disorder—Dexamethasone—multiple sclerosis	0.00211	0.00351	CcSEcCtD
Methyldopa—Psychotic disorder—Betamethasone—multiple sclerosis	0.00211	0.00351	CcSEcCtD
Methyldopa—Leukopenia—Azathioprine—multiple sclerosis	0.0021	0.0035	CcSEcCtD
Methyldopa—Cardiac failure congestive—Prednisone—multiple sclerosis	0.00207	0.00345	CcSEcCtD
Methyldopa—Abdominal distension—Triamcinolone—multiple sclerosis	0.00207	0.00344	CcSEcCtD
Methyldopa—Abdominal distension—Methylprednisolone—multiple sclerosis	0.00206	0.00344	CcSEcCtD
Methyldopa—ADRA2A—brain—multiple sclerosis	0.00205	0.00954	CbGeAlD
Methyldopa—Gastrointestinal disorder—Cladribine—multiple sclerosis	0.00203	0.00339	CcSEcCtD
Methyldopa—Weight increased—Prednisolone—multiple sclerosis	0.00203	0.00338	CcSEcCtD
Methyldopa—Constipation—Cladribine—multiple sclerosis	0.00202	0.00335	CcSEcCtD
Methyldopa—Pancreatitis—Triamcinolone—multiple sclerosis	0.00201	0.00335	CcSEcCtD
Methyldopa—Pancreatitis—Methylprednisolone—multiple sclerosis	0.00201	0.00335	CcSEcCtD
Methyldopa—Arthralgia—Azathioprine—multiple sclerosis	0.002	0.00333	CcSEcCtD
Methyldopa—Myalgia—Azathioprine—multiple sclerosis	0.002	0.00333	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—multiple sclerosis	0.00199	0.0033	CcSEcCtD
Methyldopa—DDC—Dopaminergic Neurogenesis—STAT3—multiple sclerosis	0.00194	0.0113	CbGpPWpGaD
Methyldopa—Gynaecomastia—Methotrexate—multiple sclerosis	0.00194	0.00322	CcSEcCtD
Methyldopa—SLC15A1—SLC-mediated transmembrane transport—SLC15A2—multiple sclerosis	0.00191	0.0111	CbGpPWpGaD
Methyldopa—Infection—Azathioprine—multiple sclerosis	0.0019	0.00317	CcSEcCtD
Methyldopa—Thrombocytopenia—Azathioprine—multiple sclerosis	0.00188	0.00312	CcSEcCtD
Methyldopa—Weight increased—Triamcinolone—multiple sclerosis	0.00187	0.00311	CcSEcCtD
Methyldopa—Weight increased—Methylprednisolone—multiple sclerosis	0.00187	0.00311	CcSEcCtD
Methyldopa—Body temperature increased—Cladribine—multiple sclerosis	0.00186	0.0031	CcSEcCtD
Methyldopa—Skin disorder—Azathioprine—multiple sclerosis	0.00186	0.0031	CcSEcCtD
Methyldopa—Psychotic disorder—Prednisone—multiple sclerosis	0.00184	0.00305	CcSEcCtD
Methyldopa—Infestation—Methylprednisolone—multiple sclerosis	0.00183	0.00304	CcSEcCtD
Methyldopa—Infestation NOS—Methylprednisolone—multiple sclerosis	0.00183	0.00304	CcSEcCtD
Methyldopa—Bradycardia—Prednisolone—multiple sclerosis	0.00182	0.00303	CcSEcCtD
Methyldopa—DDC—Dopaminergic Neurogenesis—TGFB1—multiple sclerosis	0.00179	0.0105	CbGpPWpGaD
Methyldopa—Musculoskeletal discomfort—Azathioprine—multiple sclerosis	0.00175	0.00291	CcSEcCtD
Methyldopa—Hypersensitivity—Cladribine—multiple sclerosis	0.00174	0.00289	CcSEcCtD
Methyldopa—Leukopenia—Mitoxantrone—multiple sclerosis	0.0017	0.00283	CcSEcCtD
Methyldopa—Weight increased—Dexamethasone—multiple sclerosis	0.0017	0.00282	CcSEcCtD
Methyldopa—Weight increased—Betamethasone—multiple sclerosis	0.0017	0.00282	CcSEcCtD
Methyldopa—Asthenia—Cladribine—multiple sclerosis	0.00169	0.00281	CcSEcCtD
Methyldopa—Bradycardia—Triamcinolone—multiple sclerosis	0.00167	0.00279	CcSEcCtD
Methyldopa—Bradycardia—Methylprednisolone—multiple sclerosis	0.00167	0.00278	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Azathioprine—multiple sclerosis	0.00165	0.00275	CcSEcCtD
Methyldopa—Abdominal distension—Prednisone—multiple sclerosis	0.00163	0.00272	CcSEcCtD
Methyldopa—Myalgia—Mitoxantrone—multiple sclerosis	0.00162	0.00269	CcSEcCtD
Methyldopa—Arthralgia—Mitoxantrone—multiple sclerosis	0.00162	0.00269	CcSEcCtD
Methyldopa—Connective tissue disorder—Methylprednisolone—multiple sclerosis	0.00161	0.00268	CcSEcCtD
Methyldopa—Diarrhoea—Cladribine—multiple sclerosis	0.00161	0.00268	CcSEcCtD
Methyldopa—Pancreatitis—Prednisone—multiple sclerosis	0.00159	0.00265	CcSEcCtD
Methyldopa—Dizziness—Cladribine—multiple sclerosis	0.00156	0.00259	CcSEcCtD
Methyldopa—Oedema—Mitoxantrone—multiple sclerosis	0.00155	0.00258	CcSEcCtD
Methyldopa—Infection—Mitoxantrone—multiple sclerosis	0.00154	0.00256	CcSEcCtD
Methyldopa—Cardiac disorder—Methylprednisolone—multiple sclerosis	0.00152	0.00254	CcSEcCtD
Methyldopa—Bradycardia—Dexamethasone—multiple sclerosis	0.00152	0.00253	CcSEcCtD
Methyldopa—Bradycardia—Betamethasone—multiple sclerosis	0.00152	0.00253	CcSEcCtD
Methyldopa—Thrombocytopenia—Mitoxantrone—multiple sclerosis	0.00152	0.00252	CcSEcCtD
Methyldopa—Body temperature increased—Azathioprine—multiple sclerosis	0.00151	0.00252	CcSEcCtD
Methyldopa—Skin disorder—Mitoxantrone—multiple sclerosis	0.0015	0.0025	CcSEcCtD
Methyldopa—Vomiting—Cladribine—multiple sclerosis	0.0015	0.00249	CcSEcCtD
Methyldopa—Erectile dysfunction—Prednisone—multiple sclerosis	0.0015	0.00249	CcSEcCtD
Methyldopa—Angiopathy—Methylprednisolone—multiple sclerosis	0.00149	0.00248	CcSEcCtD
Methyldopa—Rash—Cladribine—multiple sclerosis	0.00149	0.00247	CcSEcCtD
Methyldopa—Dermatitis—Cladribine—multiple sclerosis	0.00148	0.00247	CcSEcCtD
Methyldopa—Mediastinal disorder—Methylprednisolone—multiple sclerosis	0.00148	0.00246	CcSEcCtD
Methyldopa—Weight increased—Prednisone—multiple sclerosis	0.00148	0.00246	CcSEcCtD
Methyldopa—Headache—Cladribine—multiple sclerosis	0.00148	0.00246	CcSEcCtD
Methyldopa—Liver function test abnormal—Methotrexate—multiple sclerosis	0.00145	0.00241	CcSEcCtD
Methyldopa—SLC15A1—SLC-mediated transmembrane transport—SLC30A7—multiple sclerosis	0.00145	0.00843	CbGpPWpGaD
Methyldopa—Mental disorder—Methylprednisolone—multiple sclerosis	0.00144	0.00239	CcSEcCtD
Methyldopa—Breast disorder—Methotrexate—multiple sclerosis	0.00142	0.00236	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Methotrexate—multiple sclerosis	0.00141	0.00235	CcSEcCtD
Methyldopa—Hypersensitivity—Azathioprine—multiple sclerosis	0.00141	0.00235	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Mitoxantrone—multiple sclerosis	0.00141	0.00235	CcSEcCtD
Methyldopa—Nausea—Cladribine—multiple sclerosis	0.0014	0.00233	CcSEcCtD
Methyldopa—Paraesthesia—Mitoxantrone—multiple sclerosis	0.00139	0.00231	CcSEcCtD
Methyldopa—Angiopathy—Betamethasone—multiple sclerosis	0.00135	0.00225	CcSEcCtD
Methyldopa—Angiopathy—Dexamethasone—multiple sclerosis	0.00135	0.00225	CcSEcCtD
Methyldopa—Eosinophilia—Methotrexate—multiple sclerosis	0.00134	0.00224	CcSEcCtD
Methyldopa—Pancreatitis—Methotrexate—multiple sclerosis	0.00133	0.00221	CcSEcCtD
Methyldopa—Constipation—Mitoxantrone—multiple sclerosis	0.00132	0.0022	CcSEcCtD
Methyldopa—Bradycardia—Prednisone—multiple sclerosis	0.00132	0.0022	CcSEcCtD
Methyldopa—Diarrhoea—Azathioprine—multiple sclerosis	0.00131	0.00218	CcSEcCtD
Methyldopa—Pancytopenia—Methotrexate—multiple sclerosis	0.00129	0.00214	CcSEcCtD
Methyldopa—Connective tissue disorder—Prednisone—multiple sclerosis	0.00128	0.00213	CcSEcCtD
Methyldopa—Oedema—Prednisolone—multiple sclerosis	0.00127	0.00211	CcSEcCtD
Methyldopa—Dizziness—Azathioprine—multiple sclerosis	0.00127	0.00211	CcSEcCtD
Methyldopa—Erectile dysfunction—Methotrexate—multiple sclerosis	0.00125	0.00208	CcSEcCtD
Methyldopa—DDC—SIDS Susceptibility Pathways—BDNF—multiple sclerosis	0.00123	0.00719	CbGpPWpGaD
Methyldopa—Body temperature increased—Mitoxantrone—multiple sclerosis	0.00122	0.00204	CcSEcCtD
Methyldopa—Myalgia—Triamcinolone—multiple sclerosis	0.00122	0.00203	CcSEcCtD
Methyldopa—Vomiting—Azathioprine—multiple sclerosis	0.00122	0.00203	CcSEcCtD
Methyldopa—Myalgia—Methylprednisolone—multiple sclerosis	0.00122	0.00202	CcSEcCtD
Methyldopa—Arthralgia—Methylprednisolone—multiple sclerosis	0.00122	0.00202	CcSEcCtD
Methyldopa—Infestation NOS—Methotrexate—multiple sclerosis	0.00121	0.00201	CcSEcCtD
Methyldopa—Infestation—Methotrexate—multiple sclerosis	0.00121	0.00201	CcSEcCtD
Methyldopa—Rash—Azathioprine—multiple sclerosis	0.00121	0.00201	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.00121	0.00201	CcSEcCtD
Methyldopa—Dermatitis—Azathioprine—multiple sclerosis	0.00121	0.00201	CcSEcCtD
Methyldopa—Headache—Azathioprine—multiple sclerosis	0.0012	0.002	CcSEcCtD
Methyldopa—Angiopathy—Prednisone—multiple sclerosis	0.00118	0.00196	CcSEcCtD
Methyldopa—DDC—SIDS Susceptibility Pathways—IL10—multiple sclerosis	0.00118	0.00686	CbGpPWpGaD
Methyldopa—COMT—Transmission across Chemical Synapses—BCHE—multiple sclerosis	0.00117	0.00683	CbGpPWpGaD
Methyldopa—Oedema—Triamcinolone—multiple sclerosis	0.00117	0.00194	CcSEcCtD
Methyldopa—Infection—Triamcinolone—multiple sclerosis	0.00116	0.00193	CcSEcCtD
Methyldopa—Infection—Methylprednisolone—multiple sclerosis	0.00116	0.00193	CcSEcCtD
Methyldopa—Hepatobiliary disease—Methotrexate—multiple sclerosis	0.00114	0.0019	CcSEcCtD
Methyldopa—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.00114	0.0019	CcSEcCtD
Methyldopa—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.00114	0.0019	CcSEcCtD
Methyldopa—Paraesthesia—Prednisolone—multiple sclerosis	0.00114	0.0019	CcSEcCtD
Methyldopa—Mental disorder—Prednisone—multiple sclerosis	0.00114	0.0019	CcSEcCtD
Methyldopa—Nausea—Azathioprine—multiple sclerosis	0.00114	0.00189	CcSEcCtD
Methyldopa—Skin disorder—Methylprednisolone—multiple sclerosis	0.00113	0.00188	CcSEcCtD
Methyldopa—Agranulocytosis—Methotrexate—multiple sclerosis	0.00113	0.00188	CcSEcCtD
Methyldopa—Asthenia—Mitoxantrone—multiple sclerosis	0.00111	0.00185	CcSEcCtD
Methyldopa—Myalgia—Betamethasone—multiple sclerosis	0.00111	0.00184	CcSEcCtD
Methyldopa—Myalgia—Dexamethasone—multiple sclerosis	0.00111	0.00184	CcSEcCtD
Methyldopa—Hepatitis—Methotrexate—multiple sclerosis	0.00109	0.00181	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.00106	0.00177	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.00106	0.00177	CcSEcCtD
Methyldopa—Oedema—Dexamethasone—multiple sclerosis	0.00106	0.00176	CcSEcCtD
Methyldopa—Oedema—Betamethasone—multiple sclerosis	0.00106	0.00176	CcSEcCtD
Methyldopa—Diarrhoea—Mitoxantrone—multiple sclerosis	0.00106	0.00176	CcSEcCtD
Methyldopa—Infection—Betamethasone—multiple sclerosis	0.00105	0.00175	CcSEcCtD
Methyldopa—Infection—Dexamethasone—multiple sclerosis	0.00105	0.00175	CcSEcCtD
Methyldopa—Paraesthesia—Triamcinolone—multiple sclerosis	0.00105	0.00175	CcSEcCtD
Methyldopa—Paraesthesia—Methylprednisolone—multiple sclerosis	0.00105	0.00174	CcSEcCtD
Methyldopa—Nervous system disorder—Betamethasone—multiple sclerosis	0.00104	0.00173	CcSEcCtD
Methyldopa—Nervous system disorder—Dexamethasone—multiple sclerosis	0.00104	0.00173	CcSEcCtD
Methyldopa—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.00104	0.00173	CcSEcCtD
Methyldopa—Thrombocytopenia—Betamethasone—multiple sclerosis	0.00104	0.00173	CcSEcCtD
Methyldopa—SLC15A1—SLC-mediated transmembrane transport—SLC11A1—multiple sclerosis	0.00101	0.00589	CbGpPWpGaD
Methyldopa—Cardiac disorder—Methotrexate—multiple sclerosis	0.00101	0.00168	CcSEcCtD
Methyldopa—Angiopathy—Methotrexate—multiple sclerosis	0.000986	0.00164	CcSEcCtD
Methyldopa—Vomiting—Mitoxantrone—multiple sclerosis	0.000985	0.00164	CcSEcCtD
Methyldopa—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000979	0.00163	CcSEcCtD
Methyldopa—Rash—Mitoxantrone—multiple sclerosis	0.000977	0.00163	CcSEcCtD
Methyldopa—Dermatitis—Mitoxantrone—multiple sclerosis	0.000976	0.00162	CcSEcCtD
Methyldopa—Headache—Mitoxantrone—multiple sclerosis	0.00097	0.00161	CcSEcCtD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	0.00097	0.00565	CbGpPWpGaD
Methyldopa—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000966	0.00161	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000966	0.00161	CcSEcCtD
Methyldopa—Myalgia—Prednisone—multiple sclerosis	0.000963	0.0016	CcSEcCtD
Methyldopa—Arthralgia—Prednisone—multiple sclerosis	0.000963	0.0016	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000957	0.00159	CcSEcCtD
Methyldopa—Paraesthesia—Dexamethasone—multiple sclerosis	0.000952	0.00158	CcSEcCtD
Methyldopa—Paraesthesia—Betamethasone—multiple sclerosis	0.000952	0.00158	CcSEcCtD
Methyldopa—Mental disorder—Methotrexate—multiple sclerosis	0.000952	0.00158	CcSEcCtD
Methyldopa—Hypersensitivity—Prednisolone—multiple sclerosis	0.000936	0.00156	CcSEcCtD
Methyldopa—Body temperature increased—Triamcinolone—multiple sclerosis	0.000924	0.00154	CcSEcCtD
Methyldopa—Oedema—Prednisone—multiple sclerosis	0.000923	0.00154	CcSEcCtD
Methyldopa—Nausea—Mitoxantrone—multiple sclerosis	0.00092	0.00153	CcSEcCtD
Methyldopa—Infection—Prednisone—multiple sclerosis	0.000917	0.00153	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000915	0.00152	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000915	0.00152	CcSEcCtD
Methyldopa—Nervous system disorder—Prednisone—multiple sclerosis	0.000906	0.00151	CcSEcCtD
Methyldopa—COMT—Neuronal System—BCHE—multiple sclerosis	0.000898	0.00523	CbGpPWpGaD
Methyldopa—Skin disorder—Prednisone—multiple sclerosis	0.000897	0.00149	CcSEcCtD
Methyldopa—ADRA2A—G alpha (i) signalling events—S1PR1—multiple sclerosis	0.000884	0.00515	CbGpPWpGaD
Methyldopa—DDC—Circadian rythm related genes—FAS—multiple sclerosis	0.000862	0.00502	CbGpPWpGaD
Methyldopa—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000861	0.00143	CcSEcCtD
Methyldopa—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000859	0.00143	CcSEcCtD
Methyldopa—Leukopenia—Methotrexate—multiple sclerosis	0.000846	0.00141	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000841	0.0014	CcSEcCtD
Methyldopa—Dizziness—Prednisolone—multiple sclerosis	0.00084	0.0014	CcSEcCtD
Methyldopa—Asthenia—Triamcinolone—multiple sclerosis	0.000839	0.0014	CcSEcCtD
Methyldopa—Body temperature increased—Betamethasone—multiple sclerosis	0.000838	0.0014	CcSEcCtD
Methyldopa—Body temperature increased—Dexamethasone—multiple sclerosis	0.000838	0.0014	CcSEcCtD
Methyldopa—Asthenia—Methylprednisolone—multiple sclerosis	0.000837	0.00139	CcSEcCtD
Methyldopa—DDC—Metabolism—SRM—multiple sclerosis	0.00083	0.00484	CbGpPWpGaD
Methyldopa—Paraesthesia—Prednisone—multiple sclerosis	0.000829	0.00138	CcSEcCtD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—PLEK—multiple sclerosis	0.000805	0.00469	CbGpPWpGaD
Methyldopa—Arthralgia—Methotrexate—multiple sclerosis	0.000805	0.00134	CcSEcCtD
Methyldopa—Myalgia—Methotrexate—multiple sclerosis	0.000805	0.00134	CcSEcCtD
Methyldopa—Rash—Prednisolone—multiple sclerosis	0.000801	0.00133	CcSEcCtD
Methyldopa—Dermatitis—Prednisolone—multiple sclerosis	0.000801	0.00133	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.0008	0.00133	CcSEcCtD
Methyldopa—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000798	0.00133	CcSEcCtD
Methyldopa—Headache—Prednisolone—multiple sclerosis	0.000796	0.00132	CcSEcCtD
Methyldopa—Constipation—Prednisone—multiple sclerosis	0.00079	0.00131	CcSEcCtD
Methyldopa—Dizziness—Triamcinolone—multiple sclerosis	0.000773	0.00129	CcSEcCtD
Methyldopa—Dizziness—Methylprednisolone—multiple sclerosis	0.000771	0.00128	CcSEcCtD
Methyldopa—Infection—Methotrexate—multiple sclerosis	0.000767	0.00128	CcSEcCtD
Methyldopa—Asthenia—Betamethasone—multiple sclerosis	0.000761	0.00127	CcSEcCtD
Methyldopa—Asthenia—Dexamethasone—multiple sclerosis	0.000761	0.00127	CcSEcCtD
Methyldopa—Nervous system disorder—Methotrexate—multiple sclerosis	0.000757	0.00126	CcSEcCtD
Methyldopa—Thrombocytopenia—Methotrexate—multiple sclerosis	0.000756	0.00126	CcSEcCtD
Methyldopa—Nausea—Prednisolone—multiple sclerosis	0.000755	0.00126	CcSEcCtD
Methyldopa—ADRA2A—G alpha (i) signalling events—RGS1—multiple sclerosis	0.000752	0.00438	CbGpPWpGaD
Methyldopa—Skin disorder—Methotrexate—multiple sclerosis	0.00075	0.00125	CcSEcCtD
Methyldopa—Vomiting—Triamcinolone—multiple sclerosis	0.000743	0.00124	CcSEcCtD
Methyldopa—Vomiting—Methylprednisolone—multiple sclerosis	0.000741	0.00123	CcSEcCtD
Methyldopa—COMT—Metabolism—SRM—multiple sclerosis	0.000737	0.0043	CbGpPWpGaD
Methyldopa—Rash—Triamcinolone—multiple sclerosis	0.000737	0.00123	CcSEcCtD
Methyldopa—Dermatitis—Triamcinolone—multiple sclerosis	0.000736	0.00123	CcSEcCtD
Methyldopa—Rash—Methylprednisolone—multiple sclerosis	0.000735	0.00122	CcSEcCtD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	0.000735	0.00428	CbGpPWpGaD
Methyldopa—Dermatitis—Methylprednisolone—multiple sclerosis	0.000735	0.00122	CcSEcCtD
Methyldopa—Headache—Triamcinolone—multiple sclerosis	0.000732	0.00122	CcSEcCtD
Methyldopa—Headache—Methylprednisolone—multiple sclerosis	0.000731	0.00122	CcSEcCtD
Methyldopa—Body temperature increased—Prednisone—multiple sclerosis	0.00073	0.00121	CcSEcCtD
Methyldopa—Diarrhoea—Dexamethasone—multiple sclerosis	0.000726	0.00121	CcSEcCtD
Methyldopa—Diarrhoea—Betamethasone—multiple sclerosis	0.000726	0.00121	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000703	0.00117	CcSEcCtD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—S1PR1—multiple sclerosis	0.000703	0.0041	CbGpPWpGaD
Methyldopa—Dizziness—Betamethasone—multiple sclerosis	0.000701	0.00117	CcSEcCtD
Methyldopa—Dizziness—Dexamethasone—multiple sclerosis	0.000701	0.00117	CcSEcCtD
Methyldopa—Nausea—Triamcinolone—multiple sclerosis	0.000694	0.00116	CcSEcCtD
Methyldopa—Paraesthesia—Methotrexate—multiple sclerosis	0.000693	0.00115	CcSEcCtD
Methyldopa—Nausea—Methylprednisolone—multiple sclerosis	0.000693	0.00115	CcSEcCtD
Methyldopa—COMT—Biological oxidations—POMC—multiple sclerosis	0.000683	0.00398	CbGpPWpGaD
Methyldopa—Hypersensitivity—Prednisone—multiple sclerosis	0.00068	0.00113	CcSEcCtD
Methyldopa—Vomiting—Dexamethasone—multiple sclerosis	0.000674	0.00112	CcSEcCtD
Methyldopa—Vomiting—Betamethasone—multiple sclerosis	0.000674	0.00112	CcSEcCtD
Methyldopa—ADRA2A—Hemostasis—MERTK—multiple sclerosis	0.000672	0.00392	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—CD58—multiple sclerosis	0.000672	0.00392	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—SELPLG—multiple sclerosis	0.000672	0.00392	CbGpPWpGaD
Methyldopa—Rash—Betamethasone—multiple sclerosis	0.000669	0.00111	CcSEcCtD
Methyldopa—Rash—Dexamethasone—multiple sclerosis	0.000669	0.00111	CcSEcCtD
Methyldopa—Dermatitis—Betamethasone—multiple sclerosis	0.000668	0.00111	CcSEcCtD
Methyldopa—Dermatitis—Dexamethasone—multiple sclerosis	0.000668	0.00111	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000666	0.00111	CcSEcCtD
Methyldopa—Headache—Dexamethasone—multiple sclerosis	0.000664	0.00111	CcSEcCtD
Methyldopa—Headache—Betamethasone—multiple sclerosis	0.000664	0.00111	CcSEcCtD
Methyldopa—Asthenia—Prednisone—multiple sclerosis	0.000663	0.0011	CcSEcCtD
Methyldopa—ADRA2A—GPCRs, Class A Rhodopsin-like—GPR65—multiple sclerosis	0.000661	0.00386	CbGpPWpGaD
Methyldopa—ADRA2A—G alpha (i) signalling events—CCR1—multiple sclerosis	0.000652	0.0038	CbGpPWpGaD
Methyldopa—ADRA2A—G alpha (i) signalling events—CXCL13—multiple sclerosis	0.000652	0.0038	CbGpPWpGaD
Methyldopa—Diarrhoea—Prednisone—multiple sclerosis	0.000632	0.00105	CcSEcCtD
Methyldopa—Nausea—Dexamethasone—multiple sclerosis	0.00063	0.00105	CcSEcCtD
Methyldopa—Nausea—Betamethasone—multiple sclerosis	0.00063	0.00105	CcSEcCtD
Methyldopa—DDC—SIDS Susceptibility Pathways—IL1B—multiple sclerosis	0.000618	0.0036	CbGpPWpGaD
Methyldopa—Dizziness—Prednisone—multiple sclerosis	0.000611	0.00102	CcSEcCtD
Methyldopa—Body temperature increased—Methotrexate—multiple sclerosis	0.00061	0.00102	CcSEcCtD
Methyldopa—ADRA2A—GPCRs, Class A Rhodopsin-like—CCR1—multiple sclerosis	0.000605	0.00353	CbGpPWpGaD
Methyldopa—Vomiting—Prednisone—multiple sclerosis	0.000587	0.000977	CcSEcCtD
Methyldopa—DDC—Metabolism—CYP24A1—multiple sclerosis	0.000585	0.00341	CbGpPWpGaD
Methyldopa—DDC—Metabolism—CYP27B1—multiple sclerosis	0.000585	0.00341	CbGpPWpGaD
Methyldopa—Rash—Prednisone—multiple sclerosis	0.000582	0.000969	CcSEcCtD
Methyldopa—Dermatitis—Prednisone—multiple sclerosis	0.000582	0.000968	CcSEcCtD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—AQP4—multiple sclerosis	0.000581	0.00339	CbGpPWpGaD
Methyldopa—Headache—Prednisone—multiple sclerosis	0.000579	0.000963	CcSEcCtD
Methyldopa—Hypersensitivity—Methotrexate—multiple sclerosis	0.000569	0.000946	CcSEcCtD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—GPR65—multiple sclerosis	0.000567	0.0033	CbGpPWpGaD
Methyldopa—Asthenia—Methotrexate—multiple sclerosis	0.000554	0.000922	CcSEcCtD
Methyldopa—Nausea—Prednisone—multiple sclerosis	0.000549	0.000913	CcSEcCtD
Methyldopa—ADRA2A—GPCR ligand binding—S1PR1—multiple sclerosis	0.000535	0.00312	CbGpPWpGaD
Methyldopa—DDC—Metabolism—GPC5—multiple sclerosis	0.000535	0.00312	CbGpPWpGaD
Methyldopa—Diarrhoea—Methotrexate—multiple sclerosis	0.000528	0.000879	CcSEcCtD
Methyldopa—COMT—Metabolism—CYP24A1—multiple sclerosis	0.000519	0.00303	CbGpPWpGaD
Methyldopa—COMT—Metabolism—CYP27B1—multiple sclerosis	0.000519	0.00303	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL13—multiple sclerosis	0.000518	0.00302	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCR1—multiple sclerosis	0.000518	0.00302	CbGpPWpGaD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	0.000514	0.00299	CbGpPWpGaD
Methyldopa—Dizziness—Methotrexate—multiple sclerosis	0.00051	0.000849	CcSEcCtD
Methyldopa—Vomiting—Methotrexate—multiple sclerosis	0.000491	0.000817	CcSEcCtD
Methyldopa—Rash—Methotrexate—multiple sclerosis	0.000487	0.00081	CcSEcCtD
Methyldopa—Dermatitis—Methotrexate—multiple sclerosis	0.000486	0.000809	CcSEcCtD
Methyldopa—Headache—Methotrexate—multiple sclerosis	0.000483	0.000805	CcSEcCtD
Methyldopa—COMT—Metabolism—GPC5—multiple sclerosis	0.000475	0.00277	CbGpPWpGaD
Methyldopa—Nausea—Methotrexate—multiple sclerosis	0.000458	0.000763	CcSEcCtD
Methyldopa—DDC—SIDS Susceptibility Pathways—TNF—multiple sclerosis	0.000448	0.00261	CbGpPWpGaD
Methyldopa—DDC—Metabolism—RRM1—multiple sclerosis	0.000443	0.00258	CbGpPWpGaD
Methyldopa—ADRA2A—G alpha (i) signalling events—CXCR3—multiple sclerosis	0.000432	0.00252	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—GPR65—multiple sclerosis	0.000432	0.00252	CbGpPWpGaD
Methyldopa—ADRA2A—G alpha (i) signalling events—CCR2—multiple sclerosis	0.00042	0.00245	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PLEK—multiple sclerosis	0.000415	0.00242	CbGpPWpGaD
Methyldopa—ADRA2A—GPCRs, Class A Rhodopsin-like—PTGER4—multiple sclerosis	0.000415	0.00242	CbGpPWpGaD
Methyldopa—ADRA2A—GPCRs, Class A Rhodopsin-like—CXCR3—multiple sclerosis	0.000401	0.00234	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—CXCL13—multiple sclerosis	0.000395	0.0023	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—CCR1—multiple sclerosis	0.000395	0.0023	CbGpPWpGaD
Methyldopa—COMT—Metabolism—RRM1—multiple sclerosis	0.000394	0.00229	CbGpPWpGaD
Methyldopa—ADRA2A—GPCRs, Class A Rhodopsin-like—CCR2—multiple sclerosis	0.00039	0.00227	CbGpPWpGaD
Methyldopa—ADRA2A—G alpha (i) signalling events—CNR1—multiple sclerosis	0.000388	0.00226	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCL3—multiple sclerosis	0.000369	0.00215	CbGpPWpGaD
Methyldopa—SLC15A1—SLC-mediated transmembrane transport—ALB—multiple sclerosis	0.000364	0.00212	CbGpPWpGaD
Methyldopa—DDC—SIDS Susceptibility Pathways—IL6—multiple sclerosis	0.000362	0.00211	CbGpPWpGaD
Methyldopa—ADRA2A—GPCRs, Class A Rhodopsin-like—CNR1—multiple sclerosis	0.00036	0.0021	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—PTGER4—multiple sclerosis	0.000356	0.00207	CbGpPWpGaD
Methyldopa—ADRA2A—G alpha (i) signalling events—CXCL10—multiple sclerosis	0.000349	0.00203	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCR3—multiple sclerosis	0.000343	0.002	CbGpPWpGaD
Methyldopa—COMT—Transmission across Chemical Synapses—MAPK1—multiple sclerosis	0.000343	0.002	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCR2—multiple sclerosis	0.000334	0.00195	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CNR1—multiple sclerosis	0.000308	0.0018	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—S1PR1—multiple sclerosis	0.000303	0.00176	CbGpPWpGaD
Methyldopa—ADRA2A—G alpha (i) signalling events—CCL5—multiple sclerosis	0.0003	0.00175	CbGpPWpGaD
Methyldopa—DDC—Circadian rythm related genes—IL6—multiple sclerosis	0.000295	0.00172	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—SRM—multiple sclerosis	0.000293	0.00171	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—SELE—multiple sclerosis	0.000292	0.0017	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—CCL3—multiple sclerosis	0.000281	0.00164	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—IL2RA—multiple sclerosis	0.00028	0.00163	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL10—multiple sclerosis	0.000278	0.00162	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—S1PR1—multiple sclerosis	0.000275	0.0016	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—PTGER4—multiple sclerosis	0.000271	0.00158	CbGpPWpGaD
Methyldopa—ADRA2A—G alpha (i) signalling events—CCR5—multiple sclerosis	0.000271	0.00158	CbGpPWpGaD
Methyldopa—COMT—Neuronal System—MAPK1—multiple sclerosis	0.000262	0.00153	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—CXCR3—multiple sclerosis	0.000261	0.00152	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—RGS1—multiple sclerosis	0.000257	0.0015	CbGpPWpGaD
Methyldopa—DDC—Metabolism—BCHE—multiple sclerosis	0.000255	0.00148	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—CCR2—multiple sclerosis	0.000254	0.00148	CbGpPWpGaD
Methyldopa—ADRA2A—GPCRs, Class A Rhodopsin-like—CCR5—multiple sclerosis	0.000251	0.00146	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—GPR65—multiple sclerosis	0.000244	0.00142	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	0.000239	0.00139	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—CNR1—multiple sclerosis	0.000235	0.00137	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—RGS1—multiple sclerosis	0.000234	0.00136	CbGpPWpGaD
Methyldopa—COMT—Metabolism—BCHE—multiple sclerosis	0.000226	0.00132	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CXCL13—multiple sclerosis	0.000223	0.0013	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CCR1—multiple sclerosis	0.000223	0.0013	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—GPR65—multiple sclerosis	0.000221	0.00129	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	0.000215	0.00125	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—LINGO1—multiple sclerosis	0.000214	0.00125	CbGpPWpGaD
Methyldopa—ADRA2A—G alpha (i) signalling events—POMC—multiple sclerosis	0.000212	0.00123	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—ITGA4—multiple sclerosis	0.000211	0.00123	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—CXCL10—multiple sclerosis	0.000211	0.00123	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—IFNB1—multiple sclerosis	0.00021	0.00122	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CYP27B1—multiple sclerosis	0.000206	0.0012	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CYP24A1—multiple sclerosis	0.000206	0.0012	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—ALB—multiple sclerosis	0.000203	0.00118	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CXCL13—multiple sclerosis	0.000203	0.00118	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CCR1—multiple sclerosis	0.000203	0.00118	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GPC5—multiple sclerosis	0.000189	0.0011	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TAGAP—multiple sclerosis	0.000186	0.00108	CbGpPWpGaD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—ALB—multiple sclerosis	0.000185	0.00108	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—CCL5—multiple sclerosis	0.000182	0.00106	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	0.000168	0.000981	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	0.000165	0.000959	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—IL2—multiple sclerosis	0.000164	0.000958	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—CCR5—multiple sclerosis	0.000164	0.000955	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—S1PR1—multiple sclerosis	0.000162	0.000946	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GPC5—multiple sclerosis	0.000158	0.00092	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—RRM1—multiple sclerosis	0.000156	0.000912	CbGpPWpGaD
Methyldopa—DDC—Metabolism—APOE—multiple sclerosis	0.000153	0.000893	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PTGER4—multiple sclerosis	0.000153	0.000892	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CXCR3—multiple sclerosis	0.000148	0.000861	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—IL2RA—multiple sclerosis	0.000144	0.000842	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CCL3—multiple sclerosis	0.000144	0.000841	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CCR2—multiple sclerosis	0.000144	0.000838	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PTGER4—multiple sclerosis	0.000139	0.00081	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—RGS1—multiple sclerosis	0.000138	0.000804	CbGpPWpGaD
Methyldopa—COMT—Metabolism—APOE—multiple sclerosis	0.000136	0.000793	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CXCR3—multiple sclerosis	0.000134	0.000782	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CNR1—multiple sclerosis	0.000133	0.000773	CbGpPWpGaD
Methyldopa—DDC—Metabolism—POMC—multiple sclerosis	0.000132	0.000767	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GPR65—multiple sclerosis	0.000131	0.000763	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CCR2—multiple sclerosis	0.000131	0.000761	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—TGFB1—multiple sclerosis	0.000128	0.000747	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—POMC—multiple sclerosis	0.000128	0.000747	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—MAPK1—multiple sclerosis	0.000126	0.000733	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—CCL2—multiple sclerosis	0.000125	0.000731	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CNR1—multiple sclerosis	0.00012	0.000702	CbGpPWpGaD
Methyldopa—DDC—Metabolism—ALB—multiple sclerosis	0.00012	0.000699	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CXCL13—multiple sclerosis	0.00012	0.000698	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCR1—multiple sclerosis	0.00012	0.000698	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CXCL10—multiple sclerosis	0.000119	0.000696	CbGpPWpGaD
Methyldopa—COMT—Metabolism—POMC—multiple sclerosis	0.000117	0.000681	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CXCL10—multiple sclerosis	0.000108	0.000632	CbGpPWpGaD
Methyldopa—COMT—Metabolism—ALB—multiple sclerosis	0.000107	0.000621	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—ALB—multiple sclerosis	0.000104	0.000609	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CCL5—multiple sclerosis	0.000103	0.000599	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CCL5—multiple sclerosis	9.34e-05	0.000544	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CCR5—multiple sclerosis	9.26e-05	0.00054	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—IL2RA—multiple sclerosis	9.13e-05	0.000532	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—BCHE—multiple sclerosis	8.99e-05	0.000524	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCL3—multiple sclerosis	8.53e-05	0.000497	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—IL2—multiple sclerosis	8.47e-05	0.000494	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CCR5—multiple sclerosis	8.41e-05	0.00049	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—IL2RA—multiple sclerosis	8.29e-05	0.000483	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PTGER4—multiple sclerosis	8.21e-05	0.000478	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PGR—multiple sclerosis	8.08e-05	0.000471	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CXCR3—multiple sclerosis	7.93e-05	0.000462	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CD28—multiple sclerosis	7.85e-05	0.000458	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCR2—multiple sclerosis	7.71e-05	0.000449	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—POMC—multiple sclerosis	7.24e-05	0.000422	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CNR1—multiple sclerosis	7.12e-05	0.000415	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—TGFB1—multiple sclerosis	6.61e-05	0.000385	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—POMC—multiple sclerosis	6.57e-05	0.000383	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—MAPK1—multiple sclerosis	6.48e-05	0.000378	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CCL2—multiple sclerosis	6.43e-05	0.000375	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CXCL10—multiple sclerosis	6.41e-05	0.000373	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—TYK2—multiple sclerosis	5.84e-05	0.00034	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CD86—multiple sclerosis	5.6e-05	0.000327	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCL5—multiple sclerosis	5.52e-05	0.000321	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—APOE—multiple sclerosis	5.41e-05	0.000315	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—IL2—multiple sclerosis	5.35e-05	0.000312	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SPP1—multiple sclerosis	5.11e-05	0.000298	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCR5—multiple sclerosis	4.97e-05	0.00029	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IL2RA—multiple sclerosis	4.9e-05	0.000285	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—IL2—multiple sclerosis	4.86e-05	0.000283	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—POMC—multiple sclerosis	4.64e-05	0.000271	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—APOE—multiple sclerosis	4.52e-05	0.000264	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ALB—multiple sclerosis	4.23e-05	0.000247	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CD80—multiple sclerosis	4.09e-05	0.000238	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—POMC—multiple sclerosis	3.88e-05	0.000226	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCL2—multiple sclerosis	3.8e-05	0.000221	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—MAPK1—multiple sclerosis	3.72e-05	0.000217	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TYK2—multiple sclerosis	3.45e-05	0.000201	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IL2—multiple sclerosis	2.87e-05	0.000167	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—IL6—multiple sclerosis	2.86e-05	0.000167	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MMP9—multiple sclerosis	2.72e-05	0.000158	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—STAT3—multiple sclerosis	2.42e-05	0.000141	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MYC—multiple sclerosis	2.24e-05	0.000131	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TGFB1—multiple sclerosis	2.24e-05	0.000131	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MAPK1—multiple sclerosis	2.2e-05	0.000128	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IL6—multiple sclerosis	1.69e-05	9.84e-05	CbGpPWpGaD
